Publication | Closed Access

Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

Gastrointestinal OncologyMedicinePathologyGastrointestinal Stromal TumorsFirst-line ImatinibSecond-line SunitinibCancer TreatmentOncologyRadiation Oncology